Taking glutamine as an example, which is a key metabolic checkpoint between tumor cells and cDC1, while tumor cells compete for glutamine uptake through the SLC38A2 transporter, further impairing cDC1 function through the FLCN-TFEB signaling axis, thus inhibiting CD8+ T-cell killing activity [83]. The gene discussed is FLCN; the disease is neoplasm.